Our results confirmed that EEGS and selected metabolites (CA, and t-p-CA) could correct renal anemia by inhibiting XOD activity, reducing inflammation, and alleviating renal injury.Renal injury results in a decrease in the production of EPO, which directly results in reduced erythropoiesis, leading to anemia. This evidence concerns the gene EPO and anemia.